Institutional Fund
Jones Hill Capital LP
New York, NYCIK 21023141 filings on record
Portfolio Value
$466.47M
Q1 2026
Holdings
26
Reported positions
New Buys
0
Opened this quarter
QoQ Change
—
No prior quarter
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Biomarin Pharmaceutical Inc15.4%
- Vertex Pharmaceuticals Inc10.4%
- Vaxcyte Inc8.0%
- Nuvalent Inc6.6%
- Capricor Therapeutics Inc5.9%
- Terns Pharmaceuticals Inc5.9%
- Other47.8%
Portfolio Holdings
26 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Biomarin Pharmaceutical Inc | 1.27M | $71.65M | 15.4% | +1.27M | First Filing |
| 2 | Vertex Pharmaceuticals Inc | 108.6K | $48.50M | 10.4% | +108.6K | First Filing |
| 3 | Vaxcyte Inc | 644.8K | $37.47M | 8.0% | +644.8K | First Filing |
| 4 | Nuvalent Inc | 300.8K | $30.82M | 6.6% | +300.8K | First Filing |
| 5 | Capricor Therapeutics Inc | 909.2K | $27.64M | 5.9% | +909.2K | First Filing |
| 6 | Terns Pharmaceuticals Inc | 521.2K | $27.48M | 5.9% | +521.2K | First Filing |
| 7 | Bicara Therapeutics Inc | 1.26M | $25.06M | 5.4% | +1.26M | First Filing |
| 8 | Ani Pharmaceuticals Inc | 318.6K | $24.50M | 5.3% | +318.6K | First Filing |
| 9 | Ultragenyx Pharmaceutical In | 1.17M | $24.42M | 5.2% | +1.17M | First Filing |
| 10 | Enliven Therapeutics Inc | 593.0K | $23.25M | 5.0% | +593.0K | First Filing |
16 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio